# Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)

> **NCT01286909** · PHASE3 · UNKNOWN · sponsor: **Omicron Pharmaceuticals** · enrollment: 40 (estimated)

## Conditions studied

- Metabolic Disease

## Interventions

- **DIETARY_SUPPLEMENT:** LaFlavon

## Key facts

- **NCT ID:** NCT01286909
- **Lead sponsor:** Omicron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-01
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2011-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01286909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01286909, "Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01286909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*